Compare AGM & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | MLYS |
|---|---|---|
| Founded | 1987 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 1995 | 2023 |
| Metric | AGM | MLYS |
|---|---|---|
| Price | $223.70 | $25.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $215.00 | $48.67 |
| AVG Volume (30 Days) | 81.4K | ★ 722.4K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | 1.09 | ★ 37.43 |
| EPS | ★ 10.15 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.97 | N/A |
| Revenue Next Year | $12.21 | N/A |
| P/E Ratio | $21.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $136.57 | $22.00 |
| 52 Week High | $248.29 | $47.65 |
| Indicator | AGM | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 54.50 | 42.23 |
| Support Level | $166.64 | $22.36 |
| Resistance Level | $240.49 | $30.90 |
| Average True Range (ATR) | 5.52 | 1.09 |
| MACD | -2.21 | -0.06 |
| Stochastic Oscillator | 33.78 | 15.96 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.